4-Methylmorpholine → 3-tert-Butyl-N-(3-{6-[1-(4-methoxybenzyl)-1H-pyrazol-4-yl]-1H-imidazo[1,2-b]pyrazol-1-yl}-4-methylphenyl)-5-(4-methylpiperazin-1-yl)benzamide
反応式
F[C:2](F)(F)[C:3]([OH:5])=O.COC1C=CC([CH2:14][N:15]2[CH:19]=[C:18]([C:20]3[CH:21]=[C:22]4[N:27]([C:28]5[CH:29]=[C:30]([CH:32]=[CH:33][C:34]=5[CH3:35])[NH2:31])[CH:26]=[CH:25][N:23]4[N:24]=3)[CH:17]=[N:16]2)=CC=1.F[C:39](F)(F)C(O)=O.[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52](O)=[O:53])([CH3:48])([CH3:47])[CH3:46].CN(C(ON1N=N[C:75]2[CH:76]=[CH:77]C=N[C:74]1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CN1CCOCC1.[OH-].[Na+]>CN(C=O)C>[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52]([NH:31][C:30]1[CH:32]=[CH:33][C:34]([CH3:35])=[C:28]([N:27]2[C:22]3[N:23]([N:24]=[C:20]([C:18]4[CH:17]=[N:16][N:15]([CH2:14][C:75]5[CH:74]=[CH:2][C:3]([O:5][CH3:39])=[CH:77][CH:76]=5)[CH:19]=4)[CH:21]=3)[CH:25]=[CH:26]2)[CH:29]=1)=[O:53])([CH3:48])([CH3:47])[CH3:46]参加物
7
反応物 5
生成物 1
試薬・触媒・溶媒 1
実験手順
65 mg (0.13 mmol) of the compound of Example 8A, 50 mg (0.13 mmol) of the compound of Example 21A and 58 mg (0.15 mmol) of HATU were dissolved in 0.73 ml of DMF, 0.07 ml (0.63 mmol) of 4-methylmorpholine was added and the mixture was stirred at RT for 16 h. 10 ml of 0.1 M aqueous sodium hydroxide solution were then added, and the mixture was stirred at RT for another 10 min. The precipitate formed was filtered off, washed with water and dried under high vacuum. This gave 70 mg (76% pure, 64% of theory) of the title compound.
後処理
- stirringthe mixture was stirred at RT for another 10 min
- customThe precipitate formed
- filtrationwas filtered off
- washwashed with water
- customdried under high vacuum
出典と根拠
- ORDレコード
- ord-ce50c68d8223493abb2f064faca2495d
- 出典データセット
- uspto-grants-2016_07
- 特許番号
- US09394309B2
反応ノート
読み込み中…